Abstracts tagged "Outcome measures"

Abstract Number: 383 • 2014 ACR/ARHP Annual Meeting
How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry
Edward C. Keystone¹, Boulos Haraoui², John Kelsall³, Carter Thorne⁴, Philip Baer⁵, William Bensen⁶, Denis Choquette⁷, Regan Arendse⁸, Dalton Sholter⁹, Niall Jones¹⁰, Algis Jovaisas¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, May Shawi¹³, Allen J Lehman¹⁴ and Susan Otawa¹⁴, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²University of Montreal Hospital Centre, Montreal, QC, Canada, ³The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, ¹¹194 Main Street, University of Ottawa, Ottawa, ON, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Composite measures of disease activity can facilitate clinical decision-making to achieve treatment goals, and treating-to-target has been shown to improve outcomes. Both CRA and…
Abstract Number: 384 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)
Erin Carruthers¹, Noura AL Osaimi², Charles H Goldsmith³, Paul Adam⁴ and Diane Lacaille⁵, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁵Arthritis Research Centre of Canada, Vancouver, BC, Canada
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient involvement in monitoring their disease activity could enhance treatment by providing…
Abstract Number: 58 • 2014 ACR/ARHP Annual Meeting
What Does the Patient Global Assessment Mean for Patients with Psoriatic Arthritis? A Post-Hoc Analysis of 223 Patients with Psoriatic Arthritis
Sandra Tälli¹, Adrien Etcheto², Bruno Fautrel³, Andra Balanescu⁴, Jürgen Braun⁴, Juan D. Cañete⁵, Kurt de Vlam⁴, Maarten de Wit⁴, Turid Heiberg⁴, Philip S. Helliwell⁴, Umut Kalyoncu⁴, Uta Kiltz⁶, Mara Maccarone⁴, Dora Niedermayer⁴, Kati Otsa⁴, Rossana Scrivo⁴, Josef Smolen⁴, Tanja Alexandra Stamm⁴, Douglas J. Veale⁷, Tore K. Kvien⁴ and Laure Gossec³, ¹Rheumatology, GRC UPMC Paris 06 University, Pitie-Salpétriere hospital, Paris, France, ²Cochin Hospital, Paris Descartes University, Paris, France, ³Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁴PsAID taskforce, EULAR, Zurich, Switzerland, ⁵Rheumatology, Hospital Clinic, Barcelona, Spain, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Translational Rheumatology Research Group, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose Patient global assessment (PGA) is one of the most widely used patient reported outcomes (PROs) in psoriatic arthritis (PsA). PGA should reflect the global…
Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman² and Vinod Chandran², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…
Abstract Number: 2885 • 2013 ACR/ARHP Annual Meeting
Erosions and Sclerosis, But Not Squaring, Predict The Development Of New Syndesmophytes: A 12-Year Longitudinal Analysis (OASIS)
Sofia Ramiro¹, A.M. van Tubergen², Désirée van der Heijde³, Carmen Stolwijk⁴, Maxime Dougados⁵, Filip Van den Bosch⁶ and Robert Landewé⁷, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands
Background/Purpose: Erosions, sclerosis and squaring are included in the modified Stoke Ankylosing Spondylitis (AS) Spine Score (mSASSS). However, their value in predicting the development of…
Abstract Number: 1684 • 2013 ACR/ARHP Annual Meeting
Early Combination Immunosuppression and Serial Non-Invasive Imaging Improves Outcome In Takayasu Arteritis
Taryn Youngstein¹, Michael Quinn¹, James Peters¹ and Justin C. Mason², ¹Rheumatology Unit, Hammersmith Hospital, Imperial College London, London, United Kingdom, ²Rheumatology and Vascular Sciences, Hammersmith Hospital, Imperial College London, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) affects the aorta and its branches, pre-disposing to stenoses and aneurysmal dilatation. While morbidity remains high, evidence for efficacy of immunosuppressive…
Abstract Number: 2837 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity Leads To More Damage In The Early Phases Of Ankylosing Spondylitis: 12-Year Data From The OASIS Cohort
Sofia Ramiro¹, A.M. van Tubergen², Désirée van der Heijde³, Carmen Stolwijk⁴, Maxime Dougados⁵, Filip Van den Bosch⁶ and Robert Landewé⁷, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands
Background/Purpose: For years, it was unclear if inflammation and radiographic progression were related in ankylosing spondylitis (AS), but studies were only of short follow-up and…
Abstract Number: 1662 • 2013 ACR/ARHP Annual Meeting
Developing Guideline For Polymyalgia Rheumatica: Prioritisation Of Outcome Measures – Perspective Of Patients, General Practitioners and Rheumatologists
Yogesh Singh¹, Christian Dejaco^2,3, Sarah Mackie⁴, Daniel Ching⁵, Artur Bachta⁶, Ajesh Maharaj⁷, Alexandre Wagner⁸, Manuela Lima⁹, David Jayne¹⁰, Kevin Barraclough¹¹, Christian D Mallen¹², Stephen P. Merry¹³, Jane Hollywood¹⁴, Madeline Whitlock¹⁵, Kate Gilbert¹⁶, Pamela Hildreth¹⁶, Jennifer Nott¹⁶, Hannah Padbury¹⁶, Jean Miller¹⁶, Lorna Neill¹⁶, David Tronnier¹⁷, Pablo Perel¹⁸, Andrew Hutchings¹⁹, Dario Camellino²⁰, Steven E. Carsons²¹, William Docken²², Christina Duftner²³, Andy Abril²⁴, Robert F. Spiera²⁵, Colin T. Pease²⁶, Andreas P. Diamantopoulos²⁷, Frank Buttgereit²⁸, Peter V. Balint²⁹, Elisabeth Nordborg³⁰, Lina Bianconi³¹, Billy Fashanu¹⁵, Shunsuke Mori³², Víctor M. Martínez-Taboada³³, Maria C. Cid³⁴, Wolfgang A. Schmidt³⁵, Marco A. Cimmino³⁶, Michael Schirmer³⁷, Carlo Salvarani³⁸, Eric L. Matteson³⁹ and Bhaskar Dasgupta⁴⁰, ¹Rheumatology, Southend university hospital, Westcliff-on-sea, United Kingdom, ²Rheumatology and Immunology, Medical University Graz, Graz, Austria, ³Department of Rheumatology and Immunology, Medical University Graz, Graz A-8036, Austria, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁵Timaru Hospital, Timaru, New Zealand, ⁶Military Medical Institute, Warsaw, Poland, ⁷Prince Mshiyeni Memorial Hospital, Durban, South Africa, ⁸Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁹Universidade dos Açores, Azores, Portugal, ¹⁰Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ¹¹Hoyland House General Practice, Painswick, United Kingdom, ¹²Arthritis Research UK Primary Care Centre, University of Keele, Keele, United Kingdom, ¹³Family Medicine, Mayo Clinic, Rochester, MN, ¹⁴Rheumatology, Southend Hospital, Southend, United Kingdom, ¹⁵Southend University Hospital, Southend, United Kingdom, ¹⁶PMRGCAUK, Southend, United Kingdom, ¹⁷patients' representative, Rochester, MN, ¹⁸London School of Hygiene & Tropical Medicine, London, United Kingdom, ¹⁹Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ²⁰Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy, ²¹Div of Rheumatology, Winthrop University Hospital, Mineola, NY, ²²Brigham Orth & Arthritis Center, Chestnut Hill, MA, ²³Internal Medicine, Hopital Kufstein, Kufstein, Austria, ²⁴Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ²⁵Rheumatology, Hospital for Special Surgery, New York, NY, ²⁶Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²⁷Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²⁸Charité - Universitätsmedizin Berlin, Berlin, Germany, ²⁹Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ³⁰Sahlgenska University Hospital, Goteborg, Sweden, ³¹Ambulatorio Medicina Generale, Bibbiano, Italy, ³²Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan, ³³Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, ³⁴Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Med Ctr Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³⁷Internal medicine, Innsbruck Medical University, Innsbruck, Austria, ³⁸Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ³⁹Rheumatology, Mayo Clinic, Rochester, MN, ⁴⁰Southend University Hospital, Essex, United Kingdom
Background/Purpose: To explore similarities and differences between rheumatologists (rheum), general practitioners (GP) and patients (pt) regarding the relevance of outcome parameters in polymyalgia rheumatica (PMR).Methods:…
Abstract Number: 2852 • 2013 ACR/ARHP Annual Meeting
Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia
John S. Sampalis^1,2, Mary-Ann Fitzcharles³, Peter A. Ste-Marie⁴, Emmanouil Rampakakis^1,2 and Yoram Shir⁴, ¹JSS Medical Research, Montreal, QC, Canada, ²Jewish General Hospital, McGill University, Montreal, QC, Canada, ³Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁴Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Assessing fibromyalgia (FM) is challenging due to the lack of hard outcomes and the need to rely on patient-reported symptoms. Completion of questionnaires by…
Abstract Number: 1624 • 2013 ACR/ARHP Annual Meeting
Lupus Risk Alleles With High Ethnic Variability Worldwide Are Associated With Renal Disease In Hispanic Patients
Belinda Waltman¹, Kimberly E. Taylor², Joanne Nititham³ and Lindsey A. Criswell³, ¹Department of Medicine, University of California, San Francisco, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects minority patients. Non-European ancestry is associated with more severe disease, and conversely, European ancestry is associated with a…
Abstract Number: 2792 • 2013 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement On Juvenile Idiopathic Arthritis Quality Measures
Julia G. Harris^1,2, Esi Morgan DeWitt³, Ronald M. Laxer^4,5, Stacy P. Ardoin⁶, Beth S. Gottlieb⁷, Judyann C. Olson^1,2, Murray H. Passo⁸, Jennifer E. Weiss⁹, Daniel J. Lovell¹⁰, Tzielan C. Lee¹¹, Sheetal S. Vora^12,13, Nancy Griffin¹⁴, Jason A. Stock¹⁵, Lynn M. Darbie¹⁴ and Catherine A. Bingham¹⁶, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁷Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁸Pediatrics, Medical University of South Carolina, Charleston, SC, ⁹Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹²University of North Carolina Chapel Hill, Chapel Hill, NC, ¹³Levine Children's Hospital and Carolinas Medical Center, Charlotte, NC, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Penn State Hershey Children's Hospital, Hershey, PA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning network designed to improve outcomes of juvenile idiopathic arthritis (JIA) care. Teams…
Abstract Number: 1554 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience
Proton Rahman¹, Majed M. Khraishi², William Bensen³, John T. Kelsall⁴, Brian D. Hanna⁵, Craig Watts⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, May Shawi⁸, Susan M. Otawa⁹ and Allen J. Lehman⁹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Nexus Clinical Research, St John's, NF, Canada, ³St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Rheumatology, McMaster University, Ontario, Kitchener, ON, Canada, ⁶Department of Rheumatology, McGill University and Montreal General Hospital, Sainte-Anne-de-Bellevue, QC, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
Abstract Number: 2641 • 2013 ACR/ARHP Annual Meeting
Earlier Admission To Specialized Care, Intensified Treatment and Improved Outcome In Patients With Autoimmune Connective Tissue Disorders and Vasculitides In Germany 2011 Compared To 1995
Dörte Huscher¹, Katinka Albrecht², Katja Thiele², Sascha Bischoff², Jutta G. Richter³, Ina Kötter⁴, Wolfgang Ochs⁵ and Angela Zink¹, ¹German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴ZIRS, Centre for Interdisciplinary Rheumatology Stuttgart, Stuttgart, Germany, ⁵Rheumatologist in private practice, Bayreuth, Germany
Background/Purpose: Compared to rheumatoid arthritis and other arthritis-associated rheumatic diseases, autoimmune connective tissue disorders and vasculitides are still in the early stages of biological therapies.…
Abstract Number: 1342 • 2013 ACR/ARHP Annual Meeting
Prognosis In Espoir Rheumatoid Arthritis Cohort At 24 Months According To Remission Status At 12 Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPID3RJ1 Criteria
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Cochin Hospital, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵APHP, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Different criteria for remission in rheumatoid arthritis (RA) have been developed from a Core Data Set of 7 measures for the DAS28, SDAI, CDAI…
Abstract Number: 2536 • 2013 ACR/ARHP Annual Meeting
Lupus Impact Tracker Is Responsive To Changes In Physician Assessed Disease Status By Systemic Lupus Erythematosus Responder Index
Hervé Devilliers^1,2, Mark Kosinski³, Cindy Garris⁴ and Meenakshi Jolly⁵, ¹Clinical investigation and clinical epidemiology center (INSERM CIE01), Dijon, France, ²Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ³QualityMetric Inc, Lincoln, RI, ⁴US Health Outcomes, GlaxoSmithKline R&D, Research Triangle Park, NC, ⁵Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Lupus Impact Tracker (LIT) is a 10-item patient reported outcome tool to measure the impact of Systemic Lupus Erythematosus (SLE) or its treatment on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].